priors.science/reviews/chronic-spontaneous-urticaria-treatment

Chronic Spontaneous Urticaria Treatment

The current evidence on 18 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

18claims tracked
72primary papers reviewed
6 Jul 2026latest evidence review
Weeklyre-scored against new papers
4 Established · 10 Likely · 3 Uncertain · 0 Doubtful · 1 Refuted  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableOmalizumab 300mg for refractory chronic spontaneous urticariaOmalizumabEstablished93%5
StableRemibrutinib reduces urticaria activity scoreBTK InhibitorsEstablished88%4
StableUrticaria relapses after cyclosporineImmunosuppressionEstablished88%4
StableChronic spontaneous urticaria quality of life impairmentDisease BurdenEstablished86%3
StableBTK inhibitor versus omalizumab in chronic spontaneous urticariaBTK InhibitorsLikely78%4
StableH1 antihistamines first-line for chronic spontaneous urticariaAntihistamineLikely76%5
StableIgE predicts omalizumab responseOmalizumabLikely75%5
StableType IIb autoimmune chronic spontaneous urticaria and omalizumabBiomarkersLikely74%6
StableCyclosporine in omalizumab-refractory chronic spontaneous urticariaImmunosuppressionLikely73%5
StableOmalizumab versus cyclosporine on quality of lifeOmalizumabLikely73%5
StableAntihistamine updosing in refractory chronic spontaneous urticariaAntihistamineLikely71%4
StableOmalizumab relapse after withdrawalOmalizumabLikely69%5
StableDupilumab benefit in omalizumab-naive chronic spontaneous urticariaNovel BiologicsLikely68%2
StableChronic spontaneous urticaria spontaneous remission at five yearsDisease BurdenLikely68%4
StableBarzolvolimab mast cell depletion in chronic spontaneous urticariaNovel BiologicsUncertain62%3
StableBasophil activation test identifies autoimmune chronic spontaneous urticariaBiomarkersUncertain60%4
StableDupilumab benefit in omalizumab-refractory chronic spontaneous urticariaNovel BiologicsUncertain50%2
StableLigelizumab superiority versus omalizumabNovel BiologicsRefuted10%2
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic